[en] The diagnosis of malignant lymphoma during pregnancy is always a challenging situation, as for the patient a her family as well as for the whole medical team. Medical and communication skills are crucial in this situation. Interdisciplinary approach and a close cooperation between oncologist, obstetrician and neonatologist are equally important. The diagnosis of malignant potentially lethal disease and the need of treatment during pregnancy raise concerns about the life of mother if treatment was delayed and at the same time concerns about adverse fetal outcomes. This gives raise dilemmas at the therapeutical, ethical, moral and social levels. The patient must be included in the decisional process and the cultural as well as the religious aspects must be taken into account. (author)

[en] Diffuse large B-cell lymphoma is the most common type of malignant lymphomas. Patients with DLBCL vary in clinical presentation, prognosis and response to current therapies. This article reviews the therapy options in patients with localised and advanced DLBCL in young and elderly patients and also in patients in different special clinical situations. (author)

[en] Indolent B-cell lymphomas comprise a heterogeneous group of diseases. For patients with limited disease is local radiotherapy the treatment of choice.Watch and wait is the standard of care for patients with asymptomatic advanced stage disease. Standard first line treatment for symptomatic patients is chemo immunotherapy. The recent rediscovery of the „old“ chemotherapeutic agent bendamustin enhanced therapeutic options in indolent B-cell lymphomas. Thanks its favourable therapeutic index and effectiveness it is increasingly used in the in the first line and relapse setting as well. In patients with follicular lymphoma, the maintenance with rituximab after effective chemo immunotherapy is indicated. Earlier or later the relapse occurs in indolent lymphomas. It is the reason to have a wide variety of treatment options. In the last years we witness marked progress in the new drugs development. The new promising drugs are novel monoclonal antibodies, proteasome inhibitors, novel agents targeting a certain level of B-cell receptor signaling pathways, bcl-2 inhibitors or immunomodulatory agents. Novel agents may change our treatment approach to indolent lymphomas in the near future. (author)

[en] The treatment of Hodgkin's lymphoma has changed considerably in the last decades. This entity is now one of the most curable human malignancies. With improved survival and extended follow-up, relevance of treatment induced late effects became more evident. Therefore modern therapeutic strategies must maximize chance of cure and minimize the risk of therapy associated toxicity. Here we review the pathology of Hodgkin’s lymphoma, clinical presentation, risk stratification, current treatment approaches and toxicity of the treatment. (author)